UBS Group’s Columbia Research Enhanced Value ETF REVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$104K Buy
3,651
+3,352
+1,121% +$97.7K ﹤0.01% 6979
2025
Q4
$8.46K Buy
+299
New +$8.44K ﹤0.01% 8359
2024
Q1
Sell
-1,340
Closed -$29K 9900
2023
Q4
$29K Sell
1,340
-230
-15% -$4.75K ﹤0.01% 6862
2023
Q3
$32K Buy
1,570
+1,439
+1,098% +$30.3K ﹤0.01% 6565
2023
Q2
$2.74K Sell
131
-995
-88% -$20K ﹤0.01% 7708
2023
Q1
$22.3K Sell
1,126
-689
-38% -$13.8K ﹤0.01% 6998
2022
Q4
$35.5K Buy
1,815
+392
+28% +$7.72K ﹤0.01% 7073
2022
Q3
$25K Buy
1,423
+335
+31% +$6.57K ﹤0.01% 7102
2022
Q2
$21K Sell
1,088
-263
-19% -$5.36K ﹤0.01% 6823
2022
Q1
$29K Sell
1,351
-526
-28% -$11.1K ﹤0.01% 7037
2021
Q4
$40K Buy
+1,877
New +$39.3K ﹤0.01% 7123

Other funds holding REVS

UBS Group's REVS Position: Q1 2026 in Review

UBS Group increased its Columbia Research Enhanced Value ETF (REVS) stake by 1,121% in Q1 2026, buying an estimated $97.7K and bringing the position to 3,651 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #6979.

UBS Group first reported a position in REVS in Q4 2021 and has held it in 11 quarters since. 37 funds tracked by Wall St. Rank hold REVS as of Q1 2026.

  • UBS Group held 3,651 shares of Columbia Research Enhanced Value ETF worth $104K as of Q1 2026.
  • UBS Group bought 3,352 Columbia Research Enhanced Value ETF shares in Q1 2026, an estimated $97.7K.
  • Columbia Research Enhanced Value ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6979 holding.
  • UBS Group first reported a position in Columbia Research Enhanced Value ETF in Q4 2021 and has held it in 11 quarters since.
  • 37 funds tracked by Wall St. Rank held Columbia Research Enhanced Value ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.